Wei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Liu has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Ping Liu
Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
12 shared publications Shenglan Qi
Department of pharmacy, The NATCM Third Grade Laboratory of Traditional Chinese Medicine Preparations, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203, China
8 shared publicationsJiamei Chen
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (TCM), Institute of Liver Diseases, Shanghai University of TCM, Key Laboratory of Liver and Kidney Disease of the Ministry of Education, Clinical Key Laboratory of TCM of Shanghai
6 shared publicationsLinzhang Zhang
6 shared publications- Yong-Ping Mu
Cell Biology Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (TCM), Shanghai, China
6 shared publications - Changhong Wang
State Key Laboratory of Discovery and Utilization of Functional Components of Traditional Chinese Medicine; Key Laboratory for Standardization of Chinese Medicines, Ministry of Education; Shanghai Key Laboratory for Compound Chinese Medicines; Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1939197
Integrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents
Background: Mailuoning oral liquid (MLN), a standardized five-herb formula, is used for ischemic vascular diseases and shows potential in ameliorating dyslipidemia. Our previous study showed MLN alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via peroxisome proliferator-activated receptor α (PPARα) activation, but its comprehensive chemical profile, systemic exposure, and bioactive constituents mediating both PPARα activation and cyclooxygenase-2 (COX-2) inhibition remain unclear. Methods: High-fat, high-fructose diet-fed rats received MLN (5.4 or 10.8 mL/kg/day) for 8 weeks. Ultra-high-performance liquid chromatography coupled with Q-Exactive Orbitrap high-resolution mass spectrometry (UHPLC-Q-Exactive Orbitrap HRMS) profiled MLN chemicals and identified serum/liver prototypes. Biochemical profiles, glucose tolerance, histopathology, untargeted lipidomics, and targeted polyunsaturated fatty acid (PUFA) analysis were performed. PPARα and COX-2 signaling were examined by quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunohistochemistry. Key constituents were screened for PPARα activation via dual luciferase reporter assay and molecular docking; COX-2 inhibition was validated by enzyme assays and molecular dynamics. Results: A total of 143 compounds were characterized; 48 and 92 prototypes were enriched in serum and liver, respectively. MLN ameliorated dyslipidemia, glucose intolerance, steatosis, and inflammation. Lipidomics revealed bidirectional modulation of hepatic lipids, reversing triglyceride (TAG) accumulation and restoring phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) levels. Targeted analysis showed increased eicosapentaenoic acid (EPA) and normalized COX-2-derived prostaglandins (PGD 2 , PGE 2 ). MLN activated hepatic PPARα and downregulated COX-2. Seven serum-enriched compounds (chlorogenic acid, macranthoidin B, luteoloside, harpagide, angoroside C, oleanolic acid, betaine) were validated as direct PPARα agonists. Secologanoside and chikusetsusaponin IVa were identified as novel COX-2 inhibitors (half-maximal inhibitory concentration (IC 50 ) = 14.61 and 120.9 nM). Discussion: MLN alleviates MASLD via dual PPARα activation and COX-2 inhibition, providing a mechanistic foundation for repurposing this herbal formula in early-stage MASLD.
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1939197
Open AccessIntegrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents
Background: Mailuoning oral liquid (MLN), a standardized five-herb formula, is used for ischemic vascular diseases and shows potential in ameliorating dyslipidemia. Our previous study showed MLN alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via peroxisome proliferator-activated receptor α (PPARα) activation, but its comprehensive chemical profile, systemic exposure, and bioactive constituents mediating both PPARα activation and cyclooxygenase-2 (COX-2) inhibition remain unclear. Methods: High-fat, high-fructose diet-fed rats received MLN (5.4 or 10.8 mL/kg/day) for 8 weeks. Ultra-high-performance liquid chromatography coupled with Q-Exactive Orbitrap high-resolution mass spectrometry (UHPLC-Q-Exactive Orbitrap HRMS) profiled MLN chemicals and identified serum/liver prototypes. Biochemical profiles, glucose tolerance, histopathology, untargeted lipidomics, and targeted polyunsaturated fatty acid (PUFA) analysis were performed. PPARα and COX-2 signaling were examined by quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunohistochemistry. Key constituents were screened for PPARα activation via dual luciferase reporter assay and molecular docking; COX-2 inhibition was validated by enzyme assays and molecular dynamics. Results: A total of 143 compounds were characterized; 48 and 92 prototypes were enriched in serum and liver, respectively. MLN ameliorated dyslipidemia, glucose intolerance, steatosis, and inflammation. Lipidomics revealed bidirectional modulation of hepatic lipids, reversing triglyceride (TAG) accumulation and restoring phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) levels. Targeted analysis showed increased eicosapentaenoic acid (EPA) and normalized COX-2-derived prostaglandins (PGD 2 , PGE 2 ). MLN activated hepatic PPARα and downregulated COX-2. Seven serum-enriched compounds (chlorogenic acid, macranthoidin B, luteoloside, harpagide, angoroside C, oleanolic acid, betaine) were validated as direct PPARα agonists. Secologanoside and chikusetsusaponin IVa were identified as novel COX-2 inhibitors (half-maximal inhibitory concentration (IC 50 ) = 14.61 and 120.9 nM). Discussion: MLN alleviates MASLD via dual PPARα activation and COX-2 inhibition, providing a mechanistic foundation for repurposing this herbal formula in early-stage MASLD.
- 10 July 2026
- Published by Wiley in Journal of Separation Science
- Vol. 49 (7) , e70481
Systemic Exposure and Multicomponent Pharmacokinetics of Mailuoning Oral Liquid: Integrated Ultra‐High‐Performance Liquid Chromatography‐High‐Resolution Mass Spectrometry Profiling and Ultra‐High‐Performance Liquid Chromatography‐Tandem Mass Spectrometry Quantification
Mailuoning oral liquid (MLN) is a state‐approved multi‐herb formula that has been prescribed for 25 years to clear heat, nourish yin, invigorate blood, and resolve stasis. Although randomized controlled trials and real‐world evidence support its efficacy in thromboangiitis obliterans, deep‐vein thrombosis, and the convalescent phase of cerebral infarction, a systematic search identified no pharmacokinetic data on its bioactive constituents. This lack of pharmacokinetic data impedes evidence‐based dose refinement and international acceptance. Here, we employed ultra‐high‐performance liquid chromatography with Quadrupole‐Exactive Orbitrap high‐resolution mass spectrometry (UHPLC‐Q‐Exactive Orbitrap HRMS) to track 39 MLN‐derived compounds in rat plasma, intestinal contents, and 10 tissues; 15 with prominent systemic exposure were designated as key pharmacokinetic markers. A selective and sensitive UHPLC‐tandem MS assay was subsequently developed and fully validated for simultaneous quantification of these 15 circulating components. The assay exhibited excellent linearity ( r ≥ 0.9974) for all analytes, with precision, accuracy, extraction recovery, and matrix effects meeting standard bioanalytical validation criteria. All compounds demonstrated stability under the tested storage conditions. Following oral administration of MLN at 8.1 and 16.2 mL·kg −1 in rats, all 15 components were rapidly absorbed, reaching peak plasma concentrations within approximately 1 h. Systemic exposure increased in a clear dose‐dependent manner, with structurally related compounds showing similar pharmacokinetic profiles. Notably, the iridoids secoxyloganin, harpagide, and secologanic acid yielded the highest AUC 0 – 24 h values, indicating they are the principal systemic exposure markers. This study establishes the first comprehensive pharmacokinetic profile for MLN and provides a robust, validated analytical platform. By creating a crucial link between quantitative systemic exposure and efficacy, our work supplies a scientific foundation for refining dosage regimens, establishing quality specifications, and promoting the evidence‐based clinical application of this widely prescribed traditional Chinese medicine formula.
- 10 July 2026
- Published by Wiley in Journal of Separation Science
- Vol. 49 (7) , e70481
Systemic Exposure and Multicomponent Pharmacokinetics of Mailuoning Oral Liquid: Integrated Ultra‐High‐Performance Liquid Chromatography‐High‐Resolution Mass Spectrometry Profiling and Ultra‐High‐Performance Liquid Chromatography‐Tandem Mass Spectrometry Quantification
Mailuoning oral liquid (MLN) is a state‐approved multi‐herb formula that has been prescribed for 25 years to clear heat, nourish yin, invigorate blood, and resolve stasis. Although randomized controlled trials and real‐world evidence support its efficacy in thromboangiitis obliterans, deep‐vein thrombosis, and the convalescent phase of cerebral infarction, a systematic search identified no pharmacokinetic data on its bioactive constituents. This lack of pharmacokinetic data impedes evidence‐based dose refinement and international acceptance. Here, we employed ultra‐high‐performance liquid chromatography with Quadrupole‐Exactive Orbitrap high‐resolution mass spectrometry (UHPLC‐Q‐Exactive Orbitrap HRMS) to track 39 MLN‐derived compounds in rat plasma, intestinal contents, and 10 tissues; 15 with prominent systemic exposure were designated as key pharmacokinetic markers. A selective and sensitive UHPLC‐tandem MS assay was subsequently developed and fully validated for simultaneous quantification of these 15 circulating components. The assay exhibited excellent linearity ( r ≥ 0.9974) for all analytes, with precision, accuracy, extraction recovery, and matrix effects meeting standard bioanalytical validation criteria. All compounds demonstrated stability under the tested storage conditions. Following oral administration of MLN at 8.1 and 16.2 mL·kg −1 in rats, all 15 components were rapidly absorbed, reaching peak plasma concentrations within approximately 1 h. Systemic exposure increased in a clear dose‐dependent manner, with structurally related compounds showing similar pharmacokinetic profiles. Notably, the iridoids secoxyloganin, harpagide, and secologanic acid yielded the highest AUC 0 – 24 h values, indicating they are the principal systemic exposure markers. This study establishes the first comprehensive pharmacokinetic profile for MLN and provides a robust, validated analytical platform. By creating a crucial link between quantitative systemic exposure and efficacy, our work supplies a scientific foundation for refining dosage regimens, establishing quality specifications, and promoting the evidence‐based clinical application of this widely prescribed traditional Chinese medicine formula.
- Open Access
- 21 June 2026
- Published by Elsevier in Experimental Gerontology
- Vol. 222, 113211
Jianpi Qiangji granules improve muscle function in sarcopenia and reshape bile acid metabolism: A randomized double-blind positive-controlled trial
- 21 June 2026
- Published by Elsevier in Experimental Gerontology
- Vol. 222, 113211
Open AccessJianpi Qiangji granules improve muscle function in sarcopenia and reshape bile acid metabolism: A randomized double-blind positive-controlled trial
- 12 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 368, 121791
Fuzheng Huayu formula attenuates ductular reaction and liver fibrosis potentially through suppressing Gli1 pathway
- 12 May 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 368, 121791
Fuzheng Huayu formula attenuates ductular reaction and liver fibrosis potentially through suppressing Gli1 pathway
- Open Access
- 23 April 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1762397
Synergistic amelioration of cholestatic liver fibrosis by combined total astragalus saponins and AAV8.Numb-Exon3 through modulation of hepatic progenitor cell differentiation
Background: Despite our previous findings that both total astragalus saponins (TAS) and hepatic AAV8. Numb -Exon3 overexpression (AAV8. Numb -Ex3 OE ) are effective against cholestatic liver fibrosis (CLF), the synergistic effect and mechanism of their combination remain unknown. This study was designed to investigate this combination therapy and elucidate its underlying molecular mechanisms. Methods: A rat model of CLF was induced by bile duct ligation and subsequently treated with combination therapy. Evaluations included serum biochemical parameters, liver histopathology, hepatic hydroxyproline (Hyp) content, expression levels of key molecules in the Notch signaling pathway, hepatic progenitor cells (HPCs) differentiation, ductular reaction (DR), and liver regeneration. In vitro , WB-F344 cells were induced toward a cholangiocyte-like phenotype, and the influence of TAS on HPCs differentiation was assessed following LV. Numb -Ex3 transfection. Results: The combination therapy more effectively improved serum biochemistry, reduced hepatic inflammation and collagen deposition, and lowered hepatic Hyp content compared to TAS or AAV8. Numb -Ex3 OE monotherapy. Mechanistically, the combination therapy further suppressed differentiation of HPCs into cholangiocytes and inhibited DR, while promoting HPC-to-hepatocyte differentiation and enhancing liver regeneration. Conclusion: The combination of TAS and AAV8. Numb -Ex3 OE exerts a synergistic anti-fibrotic effect in CLF by redirecting HPCs differentiation fate. These findings provide experimental support for the development of novel combinatorial strategies against liver fibrosis.
- 23 April 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1762397
Open AccessSynergistic amelioration of cholestatic liver fibrosis by combined total astragalus saponins and AAV8.Numb-Exon3 through modulation of hepatic progenitor cell differentiation
Background: Despite our previous findings that both total astragalus saponins (TAS) and hepatic AAV8. Numb -Exon3 overexpression (AAV8. Numb -Ex3 OE ) are effective against cholestatic liver fibrosis (CLF), the synergistic effect and mechanism of their combination remain unknown. This study was designed to investigate this combination therapy and elucidate its underlying molecular mechanisms. Methods: A rat model of CLF was induced by bile duct ligation and subsequently treated with combination therapy. Evaluations included serum biochemical parameters, liver histopathology, hepatic hydroxyproline (Hyp) content, expression levels of key molecules in the Notch signaling pathway, hepatic progenitor cells (HPCs) differentiation, ductular reaction (DR), and liver regeneration. In vitro , WB-F344 cells were induced toward a cholangiocyte-like phenotype, and the influence of TAS on HPCs differentiation was assessed following LV. Numb -Ex3 transfection. Results: The combination therapy more effectively improved serum biochemistry, reduced hepatic inflammation and collagen deposition, and lowered hepatic Hyp content compared to TAS or AAV8. Numb -Ex3 OE monotherapy. Mechanistically, the combination therapy further suppressed differentiation of HPCs into cholangiocytes and inhibited DR, while promoting HPC-to-hepatocyte differentiation and enhancing liver regeneration. Conclusion: The combination of TAS and AAV8. Numb -Ex3 OE exerts a synergistic anti-fibrotic effect in CLF by redirecting HPCs differentiation fate. These findings provide experimental support for the development of novel combinatorial strategies against liver fibrosis.
- 27 February 2026
- Published by Elsevier in Phytomedicine
- Vol. 154, 158023
Xiayuxue decoction alleviates MASH by regulating gut microbiota, bile acid metabolism, and m6A modification
- 27 February 2026
- Published by Elsevier in Phytomedicine
- Vol. 154, 158023
Xiayuxue decoction alleviates MASH by regulating gut microbiota, bile acid metabolism, and m6A modification
- 22 February 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 363, 121415
Discrimination of the significance of astragalosides in Astragalus radix based on the in vivo exposure levels and pharmacokinetic characteristics of prototype saponins and their metabolites: A strategy for discovering and confirming quality markers
- 22 February 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 363, 121415
Discrimination of the significance of astragalosides in Astragalus radix based on the in vivo exposure levels and pharmacokinetic characteristics of prototype saponins and their metabolites: A strategy for discovering and confirming quality markers
- Open Access
- 20 December 2025
- Published by Elsevier in Experimental Gerontology
- Vol. 213, 113001
Therapeutic effects of Total flavonoids of Epimedium Folium on sarcopenia via modulation of gut microbiota and bile acid metabolism
- 20 December 2025
- Published by Elsevier in Experimental Gerontology
- Vol. 213, 113001
Open AccessTherapeutic effects of Total flavonoids of Epimedium Folium on sarcopenia via modulation of gut microbiota and bile acid metabolism
- 16 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 359, 121064
Compound Yujie decoction ameliorates LPS-induced acute lung injury by suppressing NLRP3 inflammasome-mediated macrophage pyroptosis
- 16 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 359, 121064
Compound Yujie decoction ameliorates LPS-induced acute lung injury by suppressing NLRP3 inflammasome-mediated macrophage pyroptosis
- 2 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 120980
Total astragalus saponins enhance the anti-liver fibrosis efficacy of Numb-overexpressed hUC-MSCs through stabilizing the Numb-p53 axis
- 2 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 120980
Total astragalus saponins enhance the anti-liver fibrosis efficacy of Numb-overexpressed hUC-MSCs through stabilizing the Numb-p53 axis